Drugs / HC006
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07477743 | Mar 2026 → Dec 2027 expected | — | HC Biopharma Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06963814 | Jul 2025 → May 2026 overdue | — | HC Biopharma Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06304571 | Feb 2024 → Mar 2026 overdue | neoplasm | HC Biopharma Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HC006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06963814 ↗ |
| Action | Deplete | “designed to selectively deplete tumor-infiltrating T regulatory cells (Tregs)” NCT06304571 ↗ |
| Modality | Monoclonal antibody | “novel therapeutic monoclonal antibody” NCT06304571 ↗ |
| Route | Intravenous | “HC006 once every 3 weeks (Q3W) by intravenous drip” NCT07477743 ↗ |
| Target | CCR8 | “specifically binds to human C-C motif chemokine receptor 8 (CCR8)” NCT06304571 ↗ |